Last reviewed · How we verify
Angiotensin II Infusion
Angiotensin II directly binds to angiotensin II receptors (AT1 and AT2) on vascular smooth muscle and other tissues to increase vasoconstriction and blood pressure.
Angiotensin II directly binds to angiotensin II receptors (AT1 and AT2) on vascular smooth muscle and other tissues to increase vasoconstriction and blood pressure. Used for Hypotension in critically ill patients refractory to conventional vasopressors.
At a glance
| Generic name | Angiotensin II Infusion |
|---|---|
| Sponsor | Massachusetts General Hospital |
| Drug class | Vasopressor agent |
| Target | Angiotensin II receptor (AT1 and AT2) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular / Critical Care |
| Phase | FDA-approved |
Mechanism of action
Angiotensin II is a potent endogenous vasoconstrictor hormone that activates angiotensin II type 1 (AT1) and type 2 (AT2) receptors. When administered as an infusion, it causes rapid vasoconstriction of arterioles and veins, increases systemic vascular resistance, and elevates blood pressure. This mechanism is used therapeutically in critically ill patients with severe hypotension refractory to other vasopressors.
Approved indications
- Hypotension in critically ill patients refractory to conventional vasopressors
Common side effects
- Hypertension
- Tachycardia
- Arrhythmias
- Thrombosis
- Ischemia
Key clinical trials
- Angiotensin II in Liver Transplantation (PHASE2, PHASE3)
- Dysfunctional Renin-Angiotensin System in Septic Shock (PHASE4)
- Early Angiotensin II in the Emergency Department (PHASE4)
- Radioembolization With Intra-arterial Angiotensin II to Improve Tumor-absorbed Dose (RADIANT) (PHASE2)
- : Vascular Function in Health and Disease (PHASE1)
- Cardiovascular Effects of Angiotensin-(1-7) in Obesity Hypertension (EARLY_PHASE1)
- Angiotensin-(1-7) Cardiovascular Effects in Aging (EARLY_PHASE1)
- Angiotensin-(1-7) and Energy Expenditure in Human Obesity (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Angiotensin II Infusion CI brief — competitive landscape report
- Angiotensin II Infusion updates RSS · CI watch RSS
- Massachusetts General Hospital portfolio CI